Pre-made Tesnatilimab benchmark antibody ( Whole mAb, anti-KLRK1 therapeutic antibody, Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-566
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-Bios-ab-566 Category Tag

Product Details

Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tesnatilimab (formerly JNJ 4500) is being developed by Janssen Biotech, for the treatment of autoimmune diseases, including Crohn’s disease.

Products Name (INN Index)

Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody

INN Name

Tesnatilimab

Target

KLRK1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Janssen Research & Development

Conditions Approved

NA

Conditions Active

Crohn's disease

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

KLRK1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous
Next
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.